ClinicalTrials.gg
RecruitingNCT03819101PEACE-4Updated May 6, 2026

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

A Phase 3 interventional study of Acetylsalicylic acid and Atorvastatin in Prostate Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 30 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 5 months later.
Phase
Phase 3
Study type
Interventional
Enrollment
1,210
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This is a 2x2 factorial randomized, multicenter, international, open phase III trial.

The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting first line treatment for CRPC

02

Conditions studied

  • Prostate Cancer

Browse trials for

03

In context

Prostatic Neoplasms

7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.

This study's planned enrollment of 1,210 is above the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 245 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate and no curative local therapy considered possible
  • Age ≥ 18 years, of at least 6 months
  • CRPC defined as tumor progression (PSA increase on at least 2 separate values separated by at least 1 week or progression on imaging) while on Androgen Deprivation Therapy (orchiectomy, LHRH agonist or -antagonist) with documented serum testosterone levels ≤ 1.7 nmol/L (≤ 0.50 ng/mL). Ongoing concurrent use of LHRH agonist or antagonist is required if the patient has not been surgically castrated
  • Presence (M1) or absence (M0) of on imaging
  • Performance status 0, 1 or 2
  • No previous use of life- prolonging treatments for CRPC (including abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, and sipuleucel-T). The use of these agents together with Androgen Deprivation Therapy (ADT) for castrate-sensitive disease is allowed.
  • Adequate renal function within 30 days prior to registration: calculated ≥ 50 mL/min, according to the formula of Cockcroft-Gault and adequate liver function with levels of and ALT ≤ 3xULN and no signs for cholestasis.
  • Participation in other clinical trials is allowed except for trials with the same primary endpoint, i.e. OS
  • Patient authorized to participate to a clinical trial by specific country regulation (eg patient affiliated to a social security system or beneficiary of the same)
  • Information delivered to patient and form signed by the patient.

Exclusion criteria

Exclusion Criteria:

  • Previous localised within 2 years with the exception of localized non-melanoma skin cancer and Ta or Tis bladder cancer (patients with asymptomatic Chronic Lymphocytic Leukemia can be included)
  • Previous malignancy within 5 years
  • Patient currently taking daily acetylsalicylic acid or a daily statin within the last 6 months
  • Patients with active liver disease ( or C, cirrhosis) or unexplained persistent elevations of serum transaminases exceeding 3 times the or cholestasis
  • Patients with excessive alcohol intake or history of a relevant liver disease
  • Known or intolerance to acetylsalicylic acid or atorvastatin or hypersensitivity to any of its components
  • to acetylsalicylic acid or atorvastatin according to label, including known high-risk for haemorrhage,
  • History of or active myopathy or significantly elevated (> 5 times ULN) CK levels
  • History of recent stroke or (TIA).
  • Any concomitant drugs contraindicated for use with the trial drugs according to the product information (e.g. Fusidic acid, potent inhibitors of or transport proteins: ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole and protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir, telaprevir, saquinavir, darunavir, fosamprenavir, boceprevir, gemfibrozil, fenofibrate, etc)
  • Any serious underlying medical condition (by the investigator's judgement) which could impair the ability of the patient to participate in the trial
  • Patients with hereditary galactose intolerance, Lapp-lactase deficiency or Glucose-Galactose-malabsorption
  • Compliance with trial medical follow-up impossible due to geographic, social or psychological reasons
  • Psychiatric disorder precluding understanding of information about trial related topics, providing , or interfering with compliance for oral drug intake
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
1,210 participants (estimated)

Study arms

  • No intervention
    Arm A

    Standard of Care (SOC) for CRPC

  • Experimental
    Arm B

    SOC + acetylsalicylic acid 100 mg daily

    Drug: Acetylsalicylic acid

  • Experimental
    Arm C

    SOC + atorvastatin 80 mg daily

    Drug: Atorvastatin

  • Experimental
    Arm D

    SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8

    Drug: Acetylsalicylic acid · Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: OS will be calculated from the date of randomization to the date of death up to 15 years

07

Study locations

15 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03819101
Collaborators
National Cancer Institute, France
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Jun 6, 2019
Primary completion
Mar 2042 (estimated)
Completion
Mar 2042 (estimated)
Last update
May 6, 2026

Study contacts

Karim Fizazi, MD, PhD
Contact
karim.fizazi@gustaveroussy.fr
+33 (0)1 42 11 43 17
Gwenael Le Teuff
Contact
gwenael.leteuff@gustaveroussy.fr
+33 (0)1 42 11 49 55

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Atorvastatin

Start the discussion